Reed Jobs: The Man Behind Yosemite’s Oncology-Focused Venture Firm
Reed Jobs is an individual who embodies the perfect blend of passion, dedication, and entrepreneurial spirit. As the founder of Yosemite, an oncology-focused venture firm launched in 2023, he is driven by a singular mission: to revolutionize the field of cancer research using cutting-edge technology and innovative approaches.
Source: techcrunch.com
Jobs’ journey with Yosemite began three years ago, when he decided to create a venture firm that would focus exclusively on oncology. This bold move was motivated by his conviction that the cures for cancer were not waiting to be discovered by pharmaceutical companies, but rather needed to be created from scratch using new knowledge and ideas.
To achieve this goal, Jobs employed a unique approach. He established Yosemite as a venture firm that would not only invest in existing biotech companies but also create new ones from scratch. To de-risk these ideas early on, Jobs used a combination of philanthropy and venture capital to support university researchers and academics in developing their projects.
One of the most significant advantages of Yosemite’s approach is its ability to create new areas of medicine before other firms can catch up. Jobs is proud of the firm’s pioneering work in epigenetic gene editing and safe delivery of gene editing to specific cells. These breakthroughs have the potential to transform the field of cancer research and make a significant impact on patient outcomes.
Yosemite’s Portfolio Companies: A Look at Azalea and Quarry
Among Yosemite’s portfolio companies, two stand out as particularly promising. Azalea, born from a grant to Jennifer Doudna’s lab, is now in the clinic and has shown significant promise in its early stages. Quarry, on the other hand, is a company built around a novel therapeutic approach called induced proximity, which involves physically dragging a disease-causing protein next to the cell’s own breakdown system.
Jobs is particularly enthusiastic about Quarry’s approach, which he believes has the potential to revolutionize the field of cancer treatment. He notes that traditional approaches to cancer treatment often involve trying to block the disease-causing protein directly, but this can be challenging and often leads to resistance. Induced proximity, on the other hand, offers a more innovative solution that could lead to better patient outcomes.
The Role of AI in Cancer Research: A Game-Changer?
Jobs is adamant that AI has the potential to revolutionize cancer research and treatment. He believes that AI can help accelerate the process of drug discovery and development by automating grunt work and providing reproducible outcomes. Moreover, AI has enabled scientists to identify pockets in proteins that were previously thought to be undruggable, opening up new avenues for cancer treatment.
One example of AI’s impact on cancer research is Revolution Medicines, a company that has developed a drug targeting the KRAS gene, a long-sought target in cancer treatment. AI has enabled Revolution Medicines to identify new variants of the KRAS gene that can be targeted, leading to significant improvements in patient outcomes.
The Future of Cancer Research: Challenges and Opportunities
Despite the progress made in cancer research, there are still significant challenges to be addressed. Jobs notes that the NIH budget has not grown in over a decade, and the current administration’s proposal to cut funding by 12% is a major concern. However, he is optimistic that the Senate and House will reject this proposal, given the bipartisan support for NIH funding.
Jobs also believes that AI has the potential to transform clinical trials, making them faster and more efficient. He notes that AI can help build synthetic control arms, reducing the number of patients needed for clinical trials and accelerating the development of new treatments.
